The purpose of this clinical trial was to evaluate the preventive effects of different doses of atorvastatin on CI-AKI in patients after CT perfusions. 688 patients undergoing CT perfusions were administered doses of atorvastatin (20 mg/day, n = 164), atorvastatin (40 mg/day, n = 178), atorvastatin (60 mg/day, n = 176) and placebo (40 mg/day, n = 170). Several factors, urinary neutrophil gelatinase-associated lipocalin (NGAL) levels, protein kinase C (PKC), nuclear factor erythroid-2 related factor 2 (Nrf2), nicotinamide adenine dinucleotide phosphate (NADPH) responsible for contrast-induced acute kidney necrosis were recorded in this study. Postoperative administration of atorvastatin decreased the risk of CI-AKI and improved renal function. 60 mg/day of atorvastatin showed best preventive effect on CI-AKI in three groups determined by Charlson Cormobidity Index (CCI) and risk, injury, failure, loss, end-stage renal disease (RIFLE). 60 mg/day of atorvastatin significantly decreased the inflammatory cytokines interleukin (IL)-1β, transforming growth factor (TGF)-β, and tumor necrosis factor (TNF)-α compared to 20 mg/day and 40 mg/day of atorvastatin in patients after multiple CT perfusions. NADPH oxidase 4 (NOX4) and p22phox expression was reduced by atorvastatin treatment. In conclusion, these outcomes indicate that 60 mg/day of atorvastatin treatment reduces the risk of CI-AKI in patients after multiple CT perfusions.

中文翻译：

---

不同剂量阿托伐他汀对多次CT灌注患者对比剂急性肾损伤的预防作用

本临床试验的目的是评价不同剂量阿托伐他汀对CT灌注后患者CI-AKI的预防作用。 688 名接受 CT 灌注的患者接受了阿托伐他汀（20 毫克/天，n = 164）、阿托伐他汀（40 毫克/天，n = 178）、阿托伐他汀（60 毫克/天，n = 176）和安慰剂（40 毫克/天）剂量。天，n = 170）。记录了导致造影剂急性肾坏死的几个因素，尿中性粒细胞明胶酶相关脂质运载蛋白 (NGAL) 水平、蛋白激酶 C (PKC)、核因子红细胞 2 相关因子 2 (Nrf2)、烟酰胺腺嘌呤二核苷酸磷酸 (NADPH)在这项研究中。术后给予阿托伐他汀可降低 CI-AKI 风险并改善肾功能。根据查尔森并发症指数（CCI）和风险、损伤、衰竭、损失、终末期肾病（RIFLE）确定，60 mg/天的阿托伐他汀在三组中显示出对 CI-AKI 的最佳预防效果。与 20 mg/天和 40 mg/天的阿托伐他汀相比，60 mg/天的阿托伐他汀显着降低了炎症细胞因子白细胞介素 (IL)-1β、转化生长因子 (TGF)-β 和肿瘤坏死因子 (TNF)-α。多次CT灌注后的患者。阿托伐他汀治疗降低了 NADPH 氧化酶 4 (NOX4) 和 p22phox 的表达。总之，这些结果表明，60 mg/天的阿托伐他汀治疗可降低多次 CT 灌注后患者发生 CI-AKI 的风险。